SCIB1, which has produced remarkable survival data treating melanoma patients in an early-stage trial, will be administered in combination with another new breed of drug called a checkpoint inhibitor.
Checkpoint inhibitors lower or break cancer’s defence against the body’s immune system, while SCIB1 uses the body’s immune system against the disease.
The SCIB1 data was one of the highlights in a busy period for the drug developer.
On Monday the company revealed it had found a partner to help it with a phase I/II clinical study of SCIB2 for patients with lung cancer.
And Scancell said a third drug, Modi-1, would likely move into first in man clinical studies for breast cancer, ovarian cancer and a rare type of bone cancer called osteosarcoma next year.
The update was provided as Scancell served up its financial results for the six months ended October 31.
As is common with companies at this formative stage of their development, Scancell was lossmaking (to the tune of £1.72mln, up from £1.17mln). At the period-end it had £4.5mln in the bank.